Answers are grounded in this paper and cite their sources.
Incorporation of serum FLC-diff into the current staging system improves risk stratification for patients with AL amyloidosis and will help develop risk-adapted therapies for AL amyloidosis.
No takes yet. Share an insight, caveat, or question.
Kumar et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: